Figure 1From: Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study MTT and plasma glucose sampling schedule at baseline, day 1 and day 28. *Shortly before MTT; †CGM was started shortly before trial drug administration and continued until 24 hours after trial drug administration. MTT: meal tolerance test. CGM, continuous glucose monitoring.Back to article page